Chemotherapy regimens, either single-agent or combination, should be considered for patients with triple-negative metastatic or recurrent breast cancer or patients with hormone receptor-positive tumors and who are at high risk for a visceral crisis. No convincing data support the superiority of ...
There are many treatment options available for this type of breast cancer, but the outlook can vary. “HER2” stands for human epidermal growth factor receptor 2. It may refer to the HER2 gene or to the protein HER2, which the gene makes.HER2 proteins are receptors that sit on the surface...
Angiogenesis has a clear and definite role in the breast cancer progression process, making antivascular endothelial growth factor (VEGF) therapies an attractive option for the treatment of metastatic breast cancer (MBC). Bevacizumab is a potent humanized monoclonal antibody to VEGF, which has shown ...
MRI background parenchymal enhancement, fibroglandular tissue, and mammographic breast density in patients with invasive lobular breast cancer on adjuvant endocrine hormonal treatment: associations with survival[J]. BCR, 2020,22(1):93. [6] Yamanouchi K, Kuba S, Eguchi S. Hormone receptor, human ...
A research team at Severance Hospital has proposed a new primary treatment strategy for HER2-negative advanced gastric cancer.The oncology team of Yonsei Cancer Center, led by Professor Rha Sun-young, conducted a treatment combining Keytruda with convent
The group of luminal (Her2 negative) is distinguished from other subtypes of breast cancer. We aimed to produce a prognostic index specific for luminal (Her2 negative) subtype breast cancer that could assist clinical treatment. The test set comprised 406 consecutive luminal (Her2 negative) breast ...
with palbociclib and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer, following rec...
Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “Despite marked progress in the treatment of HR-positive, HER2-negative breast cancer, most patients with advanced disease develop endocrine resistance and face ...
Accurate molecular classification is urgently required for guiding precision treatment. We established a large-scale multi-omics cohort of 579 patients with HR+/HER2− breast cancer and identified the following four molecular subtypes: canonical luminal, immunogenic, proliferative and receptor tyrosine ...
REVIEW Bevacizumab in the treatment of HER2-negative breast cancer Vito Lorusso Oncologic Institute,Vito Fazzi Hospital, Lecce, Italy Correspondence: Vito Lorusso P.zza Muratore, 1-73100 Lecce, Italy Tel/Fax +39 0832 661962 Email vitolorusso@inwind.it Abstract: Angiogenesis has a clear and ...